Abstract
In this issue of Cancer Cell, a paper by Lynch et al. demonstrates how the careful study of changes that occur at the interface between tumor cells and stromal cells led to the discovery of a new function for matrix metalloproteinase-7 (MMP-7) in the formation of osteolytic lesions in prostate cancer. The data suggest that MMP-7 inhibition could be a therapeutic target in prostate cancer.
MeSH terms
-
Animals
-
Carrier Proteins / metabolism
-
Gene Expression
-
Male
-
Matrix Metalloproteinase 7 / genetics
-
Matrix Metalloproteinase 7 / metabolism*
-
Membrane Glycoproteins / metabolism
-
Mice
-
Models, Biological
-
Osteoclasts / metabolism
-
Osteoclasts / pathology
-
Osteolysis / etiology
-
Osteolysis / metabolism
-
Osteolysis / pathology
-
Prostatic Neoplasms / complications
-
Prostatic Neoplasms / metabolism
-
Prostatic Neoplasms / therapy*
-
RANK Ligand
-
Rats
-
Receptor Activator of Nuclear Factor-kappa B
-
Stromal Cells / metabolism*
Substances
-
Carrier Proteins
-
Membrane Glycoproteins
-
RANK Ligand
-
Receptor Activator of Nuclear Factor-kappa B
-
Tnfrsf11a protein, mouse
-
Tnfsf11 protein, mouse
-
Matrix Metalloproteinase 7